Document resource
The treatment landscape for locoregionally advanced nasopharyngeal carcinoma (LA-NPC) is evolving, with adjuvant chemotherapy (AC) gaining renewed attention, driven by three recent pivotal randomised trials. Metronomic capecitabine for 1 year following chemoradiotherapy (CCRT) significantly improved failure-free survival (FFS) and overall survival (OS). Notably, 78% of the cohort also received induction chemotherapy (IC).1 Similarly, Miao et al reported that 6 months of adjuvant capecitabine improved FFS in LA-NPC with high-risk features, although no OS benefit was observed in the intention to treat cohort.2 Most recently, Liu et al compared two intravenous adjuvant regimens, demonstrating that gemcitabine plus cisplatin (GP) outperformed the traditional fluorouracil plus cisplatin (PF).3 Collectively, these studies affirmed that both oral and intravenous AC can improve outcomes in selected patients with LA-NPC—yet the optimal regimen remains to be defined.